Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Collegium Pharmaceutical (COLL) Amortization of Deferred Charges: 2013-2024

Historic Amortization of Deferred Charges for Collegium Pharmaceutical (COLL) over the last 9 years, with Dec 2024 value amounting to $6.0 million.

  • Collegium Pharmaceutical's Amortization of Deferred Charges rose 11.18% to $1.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.5 million, marking a year-over-year decrease of 16.26%. This contributed to the annual value of $6.0 million for FY2024, which is 30.33% down from last year.
  • Latest data reveals that Collegium Pharmaceutical reported Amortization of Deferred Charges of $6.0 million as of FY2024, which was down 30.33% from $8.6 million recorded in FY2023.
  • In the past 5 years, Collegium Pharmaceutical's Amortization of Deferred Charges registered a high of $9.0 million during FY2020, and its lowest value of $3.4 million during FY2021.
  • Moreover, its 3-year median value for Amortization of Deferred Charges was $8.3 million (2022), whereas its average is $7.6 million.
  • As far as peak fluctuations go, Collegium Pharmaceutical's Amortization of Deferred Charges slumped by 62.04% in 2021, and later skyrocketed by 143.25% in 2022.
  • Yearly analysis of 5 years shows Collegium Pharmaceutical's Amortization of Deferred Charges stood at $9.0 million in 2020, then slumped by 62.04% to $3.4 million in 2021, then surged by 143.25% to $8.3 million in 2022, then increased by 4.22% to $8.6 million in 2023, then tumbled by 30.33% to $6.0 million in 2024.